|
|
 |
|
Viewing report
|
|
|
|
Systemic Fungal Infection Therapeutics Market – Thailand
Frost & Sullivan, Nov 2009, Pages: 39
This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Thailand.
Research Overview
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market – Thailand provides competitive structure, market analysis, and future trends. In this research, Frost & Sullivan's expert analysts conducted primary research with the following systemic fungal infection (SFI) treaters: hematologists, ICU physicians, and infectious disease specialists.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
Advancements in Diagnostic Tests to Promote a More Targeted Approach to the Treatment of Systemic Fungal Infections
Technological advancements in therapeutics are expected to amplify the number of patients diagnosed with SFI in Thailand over the next five years. The significant increase in number of patients is shifting the focus of managing SFI from empiric and prophylactic methods to targeted and pre-emptive treatment. The SFI therapeutics market is also likely to receive a shot in the arm with a high premium on products that are capable of tackling emergent, problematic pathogens. As more resistant pathogens in SFI emerge, therapies will revolve around ensuring that the right treatment is administered. This is made possible through non-microbiologic and clinical diagnostic techniques (Platelia, Fungitell, and PNA FISH®) to identify the onset of infection.
Although there are key therapeutics to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Doctors are under increasing pressure to ensure that they choose the right course of treatment the first time, based on the universal criteria of risk factors, clinical, radiological, microbiological, or other diagnostic evidence. “This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices,” says the analyst of this research. “As a result, there would be a reduction in the use of prophylaxis in the ‘at risk’ patient group, and empiric therapy in patients groups with a persistent fever or other suggestive symptoms.”
Given the relatively niche nature of SFI, it is important for key participants to differentiate their products, especially as advancements in diagnostic techniques restrict prescriptions to specific therapeutic uses. As therapeutics shift from broad and empiric indications, pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and subspecies) and patient population. This enables greater differentiation, thereby protecting the specific drug from generic erosion in the future. “The changing epidemiology of causative pathogens has caused a decline in the effectiveness of existing therapeutic options,” notes the analyst. “Pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups (solid organ transplant patients, cancer patients, neonates, HIV/AIDS patients, and surgery patients).”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
By Treaters:
- Hematologists
- ICU physicians
- Infectious disease specialists
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Rheumatoid Arthritis Therapeutics Market in Thailand
Hepatitis C Therapeutics Market—Thailand
Molecular Diagnostics - Technologies, Markets and Companies
Emerging Medical Technologies Spotlight, a Report of Investment & Partnering Opportunities 2010
Hepatitis C Therapeutics Market – Taiwan
Emerging Medical Technologies Spotlight, A Report Of Investment & Partnering Opportunities, 2011
Mayo Clinic Antimicrobial Therapy: Quick Guide
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Hong Kong
Clinical Laboratory Testing Volume 1: Reagents and Instruments
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
|
|
|
|
